Fig. 3From: The potential of deferasirox as a novel therapeutic modality in gastric cancerEffect of deferasirox on iron metabolism and other pathways. a Treatment with deferasirox for 24 h resulted in an increased level of TFR1 and a decreased level of ferroportin. b Deferasirox also induced apoptosis, upregulated NDRG1, and downregulated p-mTOR and c-myc as assessed by Western blot analysisBack to article page